Iantrek is a technology company.
Iantrek is redefining what’s possible in micro-interventional ophthalmic surgery. We’re advancing next-generation technologies to transform total-outflow enhancement.
Iantrek has raised $42.0M across 1 funding round.
Iantrek has raised $42.0M in total across 1 funding round.
Iantrek is a pioneering ophthalmic medical technology company specializing in micro- and bio-interventional solutions for glaucoma surgery. Founded in 2019 and headquartered in White Plains, New York, with R&D in Providence, Rhode Island, Iantrek develops minimally invasive glaucoma surgery (MIGS) devices targeting the eye's natural outflow pathways—trabecular and suprachoroidal—to reduce intraocular pressure (IOP) in chronic eye disease patients.[1][2][5] Key products include the CycloPen™ System for suprachoroidal access, AlloFlo™ Uveo (an allogeneic bio-tissue implant for uveoscleral outflow, now commercially launching post-$42M Series C funding), and C-Rex™ Device for trabecular meshwork excision, with clinical data showing up to 42% IOP reduction at 12 months and 74% of eyes achieving ≥20% reduction at 2 years.[1][3][5] Serving glaucoma surgeons and patients, Iantrek addresses limitations of traditional treatments by offering precise, hardware-free options that enhance outflow without stents, backed by $70M+ in funding (Series B: $28M; Series C: $42M) and 11 patents.[2][3]
The company has strong growth momentum, with AlloFlo Uveo completing first-in-human trials, 3,000+ U.S. cases, and 7 peer-reviewed studies ahead of full launch; next-gen products like AlloSert Uveo and C-Rex Duo are in development for 2026 commercialization.[3][5][6]
Iantrek was founded in 2019 by Dr. Sean Ianchulev, MD, MPH, a renowned ophthalmology innovator and Professor at the Icahn School of Medicine at Mount Sinai.[1][3] Ianchulev's background in eye care drove the company's creation to tackle unmet needs in chronic eye diseases, particularly glaucoma, through advanced surgical interventions.[1][5] Early traction came from developing the CycloPen System and CREST Registry study, which demonstrated significant IOP reductions, positioning Iantrek as a leader in dual-outflow MIGS.[1][4] Pivotal moments include FDA-registered technologies and securing investments from Visionary Venture Fund, Civilization Ventures, Versant Ventures, Canaan Partners, USVP, and aMoon Fund, culminating in the $42M Series C in 2025 to fuel AlloFlo Uveo's U.S. launch.[2][3]
Iantrek stands out in the ophthalmic medtech space through:
Iantrek rides the MIGS wave in ophthalmology, where rising glaucoma prevalence (affecting millions globally) demands less invasive alternatives to drops or traditional surgery amid an aging population and medtech boom.[1][3] Timing is ideal post-COVID surgical backlogs and payer shifts favoring outpatient procedures; market forces like FDA nods for outflow tech and investor enthusiasm (e.g., $42M Series C) favor scalable bio-interventions over hardware stents.[2][3][6] Iantrek influences the ecosystem by redefining glaucoma paradigms—shifting to "Bio-intervention™" with natural tissue integration—empowering surgeons (e.g., via controlled trabeculorrhexis) and inspiring competitors in a $5B+ eye care device market.[1][5]
Iantrek is poised for explosive growth with AlloFlo Uveo's 2025-2026 U.S. launch, leveraging 3,000 cases and clinical wins to capture MIGS share, followed by AlloSert Uveo and trabecular expansions like C-Rex Duo.[3][5][6] Trends like AI-precision surgery, bio-fabrication, and value-based care will amplify its edge, potentially evolving it into a full ophthalmic platform leader. As the only dual-outflow pioneer, Iantrek could redefine glaucoma care, delivering sustained IOP control to millions—watch for acquisition buzz or global expansion.[1][2][3]
Iantrek has raised $42.0M in total across 1 funding round.
Iantrek's investors include aMoon Fund, Casey Tansey, U.S. Venture Partners.
Iantrek has raised $42.0M across 1 funding round. Most recently, it raised $42.0M Series C in August 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2025 | $42.0M Series C | aMoon Fund, Casey Tansey, U.S. Venture Partners |